CELC Celcuity Inc.
Debt Financing ·
Celcuity issued $575,000,000 of 0.250% convertible senior notes due 2032 on June 8, 2026, with net proceeds of approximately $557.0 million. It repaid its loan agreement in full the same day.
Celcuity priced $500,000,000 of 0.250% convertible senior notes due 2032, upsized from $400,000,000, with a 30-day option for $75,000,000 more. The company plans to use the proceeds first to repay its Oxford Finance loan.
The notes mature on August 1, 2032, carry an initial conversion price of approximately $124.53 a share, and will repay the Oxford Finance and Innovatus loan in full. The last reported sale price on June 2, 2026 was $91.42.
Celcuity drew $30 million at closing, bringing the term loan to $130 million. The $170 million of new committed capital depends on FDA approval of gedatolisib or on commercial revenue milestones.
Celcuity (Nasdaq: CELC) sold $201,250,000 of 2.750% convertible notes due 2031, including an over-allotment option the underwriters exercised on July 30, 2025. The notes convert at an initial price of about $51.30 per share, and the company sold stock and pre-funded warrants in a separate, concurrent offering.
The supplement covers up to $125,000,000 of common stock sold through Jefferies LLC under a February 4, 2022 sales agreement. Shares with an aggregate offering price of up to $22,182,550 remained unsold under the 2022 supplement, and the filing gives a $12.71 last sale price on December 4, 2024.
Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. Its lead candidate, gedatolisib, is a kinase inhibitor that binds all class I PI3K isoforms and the mTORC1 and mTORC2 complexes, inhibiting the PI3K/AKT/mTOR pathway. In the Phase 3 VIKTORIA-1 trial in hormone receptor-positive, HER2-negative advanced breast cancer, detailed results were reported for the PIK3CA wild-type cohort, and enrollment was completed in the PIK3CA mutant cohort. The Phase 3 VIKTORIA-2 trial evaluates gedatolisib with a CDK4/6 inhibitor and fulvestrant as first-line treatment and is ongoing. A Phase 1b/2 trial, CELC-G-201, is evaluating gedatolisib with darolutamide in metastatic castration resistant prostate cancer. Gedatolisib has Fast Track and Breakthrough Therapy designations for hormone receptor-positive advanced breast cancer after progression on CDK4/6 therapy. The FDA accepted the new drug application for gedatolisib on January 16, 2026, granting Priority Review under the Real-Time Oncology Review program, with a target user fee goal date of July 17, 2026.
| Product or program | What it is | Stage |
|---|---|---|
| Gedatolisib | PI3K/AKT/mTOR pathway kinase inhibitor for hormone receptor-positive, HER2-negative advanced breast cancer | NDA accepted, Priority Review |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $145.0 million | $104.2 million |
| Net income (loss) | -$177.0 million | -$111.8 million |
| Cash from operations | -$153.3 million | -$83.5 million |
| Cash and equivalents | $165.7 million | $22.5 million |
| Short-term investments | $275.8 million | $212.6 million |
Our latest story on this, dated Jun 8, 2026: "Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 8, 2026: "Celcuity completes $575,000,000 convertible notes offering, repays Oxford and Innovatus loan". The story links the filing or release it is based on. Read the story.
Celcuity Inc. trades under the ticker CELC on NASDAQ.
Celcuity Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Celcuity Inc. is 1603454. Its filings are on SEC EDGAR.
48,931,908 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Celcuity Inc. under United States.
Our directory classifies Celcuity Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Celcuity Inc. is US15102K1007.
aibio.space lists Celcuity Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. Its lead candidate, gedatolisib, is a kinase inhibitor that binds all class I PI3K isoforms and the mTORC1 and mTORC2 complexes, inhibiting the PI3K/AKT/mTOR pathway.
Gedatolisib: PI3K/AKT/mTOR pathway kinase inhibitor for hormone receptor-positive, HER2-negative advanced breast cancer Stage: NDA accepted, Priority Review.
Celcuity Inc. reported a net loss of $177.0 million for the fiscal year ended Dec 31, 2025, and used $153.3 million of cash in operations, per its annual report to the SEC.
$145.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio